Trial Profile
Sirolimus Versus AntiVEGF for Wet AMD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Aflibercept; Bevacizumab; Ranibizumab
- Indications Age-related macular degeneration; Choroidal neovascularisation
- Focus Therapeutic Use
- 12 Jan 2017 Status changed from active, no longer recruiting to completed.
- 19 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
- 19 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016.